• 1
    Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 43345.
  • 2
    Robinson M. Medical management of gastroesophageal reflux disease. In: CastellDO, RichterJE, eds. The Esophagus, 3rd edn. Lippincott, Williams & Wilkins, Philadelphia, 1999: 447–62.
  • 3
    Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 136370.
    Direct Link:
  • 4
    Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 45564.
  • 5
    Gardner JD, Sloan S, Miner PB Jr, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastroesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 94553.
  • 6
    Gardner JD, Sloan S, Miner PB Jr, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathologic esophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 95564.
  • 7
    Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 128593.
  • 8
    McNeil BJ, Keeler E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975; 293: 2115.
  • 9
    Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 2936.
  • 10
    Hanley JA, McNeil BJ. The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 83943.
  • 11
    Motulsky H. Interpreting laboratory tests: Introduction to Bayesian thinking. In: Intuitive Biostatistics. Oxford University Press, New York, 1995: 12939.
  • 12
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 13
    Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for detection of gastroesophageal reflux disease. Gastroenterology 1987; 93: 8590.
  • 14
    Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal monitoring. normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gstroenterol 1992; 87: 110211.
  • 15
    Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193201.
  • 16
    Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11: 113741.
  • 17
    Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386406.
  • 18
    Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 14848.